TrialBreast cancer research and treatment2025

Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial.

Axel Stenmark Tullberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.